Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05226871 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies

StatusActive, Not Recruiting
PhasePhase 2
SponsorPfizer
Started2022-07-07
View on ClinicalTrials.gov ↗
The purpose of this clinical trial is to provide study medicine(s) and learn about their safety. This study is seeking participants who: * Have benefited from ongoing study treatment as determined by the study doctor in a Pfizer-sponsored palbociclib Parent Study * Must agree to follow the reproductive criteria * Are willing and able to comply with all scheduled visits, treatment plans, and other study procedures * Can give signed informed consent documents Participants in this study will continue to receive treatment as they were in the parent study. The time by which participants will take part in this study is retrospective (after completed parent study). We will examine the experiences of people receiving the study medicine(s). This will help us determine if the study medicine(s) are safe. During this time, the participants will be monitored for the safety of the study medicine(s).

Amendment history 2 changes detected by DataLookout

2026-09-10
Primary completion pushed: 2026-12-31 → 2029-12-31
2026-09-10
Completion pushed: 2026-12-31 → 2029-12-31
Trial Details
NCT Number NCT05226871
Lead Sponsor Pfizer
Conditions Breast Cancer, Head and Neck Cancer
Enrollment 35 participants
Start Date 2022-07-07
Primary Completion 2029-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-09-09